Related Experiment Video

Updated: May 13, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy: a case

Kavitha Muthiah1, Justin Phan, Desiree Robson

  • 1Heart Failure and Transplant Unit, St. Vincent's Hospital, Darlinghurst, Australia.

ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|February 27, 2013
PubMed

Insights

Centrifugal continuous-flow left ventricular assist device (cfLVAD) therapy shows promise for hypertrophic cardiomyopathy (HCM) patients. This study found that HCM patients experienced significant short-to-medium term benefits, similar to dilated cardiomyopathy (DCM) patients.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Left ventricular assist device (LVAD) therapy is standard for end-stage dilated cardiomyopathy (DCM).
  • Hypertrophic cardiomyopathy (HCM) patients are typically excluded from LVAD therapy.
  • Limited data exists on LVAD outcomes in HCM patients.

Purpose of the Study:

  • To compare the outcomes of centrifugal continuous-flow left ventricular assist device (cfLVAD) therapy in patients with hypertrophic cardiomyopathy (HCM) versus dilated cardiomyopathy (DCM).
  • To evaluate the efficacy and safety of cfLVAD in HCM patients with end-stage heart failure.

Main Methods:

  • Retrospective analysis comparing 3 HCM patients with 36 DCM patients receiving cfLVAD therapy.
  • Assessment of clinical outcomes including pump flows, pulmonary arterial pressures, and cardiac index.

Main Results:

  • HCM patients had smaller left ventricular end-diastolic dimensions compared to DCM patients.
  • Average pump flows were similar between HCM and DCM groups.
  • Both HCM and DCM groups showed marked improvement in mean pulmonary arterial pressures and cardiac index at 5 months.

Conclusions:

  • Centrifugal cfLVAD therapy offers significant short-to-medium term benefits for patients with end-stage heart failure due to HCM.
  • HCM patients can benefit from cfLVAD therapy, challenging previous exclusion criteria.
  • Further research is warranted to explore long-term outcomes in HCM patients undergoing LVAD therapy.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...